Cargando…
Safety and efficacy of a modified-live canine coronavirus vaccine in dogs
The safety and the efficacy of a modified-live (ML) canine coronavirus (CCoV) vaccine strain 257/98-3c was evaluated in 14 dogs seronegative and virus negative for CCoV. For the safety test, four dogs were inoculated, two by intramuscular and two by oronasal route, with 10 times the vaccinal dose. D...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117189/ https://www.ncbi.nlm.nih.gov/pubmed/15019110 http://dx.doi.org/10.1016/j.vetmic.2003.07.009 |
_version_ | 1783514314947166208 |
---|---|
author | Pratelli, A Tinelli, A Decaro, N Martella, V Camero, M Tempesta, M Martini, M Carmichael, L.E Buonavoglia, C |
author_facet | Pratelli, A Tinelli, A Decaro, N Martella, V Camero, M Tempesta, M Martini, M Carmichael, L.E Buonavoglia, C |
author_sort | Pratelli, A |
collection | PubMed |
description | The safety and the efficacy of a modified-live (ML) canine coronavirus (CCoV) vaccine strain 257/98-3c was evaluated in 14 dogs seronegative and virus negative for CCoV. For the safety test, four dogs were inoculated, two by intramuscular and two by oronasal route, with 10 times the vaccinal dose. During the observation period (28 days) all dogs did not display any local or systemic reaction. For the efficacy test, eight dogs were vaccinated by intramuscular (four dogs—group A) or by oronasal route (four dogs—group B). Two dogs were maintained as non-vaccinated controls. In the dogs of group A, vaccinal virus was not detected in faecal samples by virus isolation (VI) and by PCR assay, while in the dogs of group B, the virus was revealed for six median days only by PCR. Twenty-eight days later, the vaccinated and control dogs were challenged with a field CCoV strain. After the challenge, the vaccinated dogs did not display clinical signs and the dogs of group A shed virus for 5.5 median days, evaluated by VI, and for 10 median days evaluated by PCR. Virus shedding was not observed, both by VI and PCR assay, in the dogs of group B. The two control dogs displayed moderate clinical signs and the virus was detected by VI for 14.5 median days starting from day 3 post-challenge (dpc 3) and by PCR assay for 23 median days starting from dpc 1. |
format | Online Article Text |
id | pubmed-7117189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71171892020-04-02 Safety and efficacy of a modified-live canine coronavirus vaccine in dogs Pratelli, A Tinelli, A Decaro, N Martella, V Camero, M Tempesta, M Martini, M Carmichael, L.E Buonavoglia, C Vet Microbiol Article The safety and the efficacy of a modified-live (ML) canine coronavirus (CCoV) vaccine strain 257/98-3c was evaluated in 14 dogs seronegative and virus negative for CCoV. For the safety test, four dogs were inoculated, two by intramuscular and two by oronasal route, with 10 times the vaccinal dose. During the observation period (28 days) all dogs did not display any local or systemic reaction. For the efficacy test, eight dogs were vaccinated by intramuscular (four dogs—group A) or by oronasal route (four dogs—group B). Two dogs were maintained as non-vaccinated controls. In the dogs of group A, vaccinal virus was not detected in faecal samples by virus isolation (VI) and by PCR assay, while in the dogs of group B, the virus was revealed for six median days only by PCR. Twenty-eight days later, the vaccinated and control dogs were challenged with a field CCoV strain. After the challenge, the vaccinated dogs did not display clinical signs and the dogs of group A shed virus for 5.5 median days, evaluated by VI, and for 10 median days evaluated by PCR. Virus shedding was not observed, both by VI and PCR assay, in the dogs of group B. The two control dogs displayed moderate clinical signs and the virus was detected by VI for 14.5 median days starting from day 3 post-challenge (dpc 3) and by PCR assay for 23 median days starting from dpc 1. Elsevier B.V. 2004-03-26 2004-01-15 /pmc/articles/PMC7117189/ /pubmed/15019110 http://dx.doi.org/10.1016/j.vetmic.2003.07.009 Text en Copyright © 2003 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Pratelli, A Tinelli, A Decaro, N Martella, V Camero, M Tempesta, M Martini, M Carmichael, L.E Buonavoglia, C Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title | Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title_full | Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title_fullStr | Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title_full_unstemmed | Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title_short | Safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
title_sort | safety and efficacy of a modified-live canine coronavirus vaccine in dogs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117189/ https://www.ncbi.nlm.nih.gov/pubmed/15019110 http://dx.doi.org/10.1016/j.vetmic.2003.07.009 |
work_keys_str_mv | AT pratellia safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT tinellia safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT decaron safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT martellav safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT camerom safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT tempestam safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT martinim safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT carmichaelle safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs AT buonavogliac safetyandefficacyofamodifiedlivecaninecoronavirusvaccineindogs |